Status: Recruiting
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The secondary objective is to assess the safety and tolerability of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The exploratory objective is to investigate the pharmacokinetic and pharmacodynamic characteristics of hUC-MSCs injection in patients with AIS.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Wingor Biotechnology Co., Ltd.Updated: Sep 29, 2025Locations: 1
Eligibility criteria
Age 18 to 75 years, inclusive, regardless of gender. [+6]
Planned or already undergone thrombolysis or thrombectomy for this stroke. [+12]